{"id":"NCT01621672","sponsor":"University of Arkansas","briefTitle":"UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma","officialTitle":"Myeloma Cure Project: Prospective, Randomized Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma Who Have Completed 3 Years of VTD/TD or VTD or VRD Maintenance on Total Therapy 3 (TT3) Trials 2003-33 and 2006-66","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04","primaryCompletion":"2014-08","completion":"2014-08","firstPosted":"2012-06-18","resultsPosted":"2015-09-10","lastUpdate":"2015-10-19"},"enrollment":42,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Revlimid","otherNames":["Lenalidomide"]}],"arms":[{"label":"Revlimid","type":"EXPERIMENTAL"},{"label":"No further treatment","type":"NO_INTERVENTION"}],"summary":"The purpose of this study is to determine in a phase II trial, whether further maintenance therapy with Revlimid can extend the duration of progression-free survival and the duration of complete or near complete response compared to no further therapy beyond the TT3 protocol-prescribed 3 years of maintenance with 1 year of VTD plus 2 years with TD, 3 years with VTD (2003-33) or VRD (2006-66).","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"2 years","effectByArm":[{"arm":"Revlimid","deltaMin":88,"sd":null},{"arm":"Observation","deltaMin":71,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":15,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":25},"commonTop":["Grade 1 Hypoalbuminemia","Grade 1 Creatinine increase","Grade 1 Thrombocytopenia","Grade 1 Hypokalemia","Grade 2 Sensory/Neuropathy"]}}